Ribociclib plus endocrine therapy for early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies whether adding ribociclib to standard hormone (endocrine) therapy lowers the risk of breast cancer coming back in early-stage, hormone-receptor–positive cancer. It mainly looks at safety and how well the treatment controls cancer after surgery and (sometimes) prior hormone treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign consent.
- Your breast cancer tests positive for estrogen and/or progesterone receptors.
- Your tumor is HER2-negative (not HER2-amplified on lab testing).
- Your cancer has been removed by surgery and you do not have distant spread or proven recurrence.
- You can take hormone therapy for prevention (no major medical reasons you cannot).
- Your heart testing looks safe (special ECG/QT and resting heart rate in the allowed range).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding ribociclib (a targeted pill) to hormone therapy can control breast cancer that has come back in the breast area or nearby lymph nodes/chest wall. It targets hormone-receptor–positive and HER2-negative tumors to help slow disease after local treatment.
This trial tests a new approach: starting with a targeted pill (ribociclib) plus hormone therapy (an aromatase inhibitor), instead of immediate chemotherapy, for women with a specific type of breast cancer (ER low-positive, HER2-negative) that is growing quickly. If eligible, you would not have received any prior treatment for your advanced cancer.
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
This study observes people with early-stage hormone receptor positive, HER2-negative breast cancer who are taking ribociclib (Kisqali) with hormone therapy after surgery. It aims to see how well the treatment works and how safe it is in real life.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.